Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Magic Power Coffee reveals a recall

This article was originally published in The Tan Sheet

Executive Summary

The distributors of Magic Power Coffee do not have a trick up their sleeve to make their product disappear from the market, but must rely on a recall. INZ Distributors Inc./Magic Power Coffee Inc. June 28 voluntarily recalled the dietary supplement in which FDA found hydroxythiohomosildenafil, an unapproved drug that is an analogue to sildenafil, the active ingredient in Pfizer's erectile dysfunction drug Viagra (1"The Tan Sheet" June. 28, 2010). The Brooklyn, N.Y., firm said no illnesses linked to the product have been reported. The recall covers production dates through May 8, 2010

You may also be interested in...

FDA brews up Magic Power Coffee warning

The distributor of a coffee product found to contain an analogue of the erectile dysfunction drug sildenafil receives an official FDA warning letter Aug. 23, following a consumer advisory and voluntary recall in June (1"The Tan Sheet" July 5, 2010, In Brief). INZ Distributors of Brooklyn, N.Y., sells an unapproved, misbranded new drug, the agency's New York District office says. Magic Power Coffee is an adulterated food, due to the presence of an ingredient not generally recognized as safe, and improperly labeled as a dietary supplement given its representation as a conventional food/beverage, FDA says. INZ faces product seizures and possible injunction if it fails to correct the violations within 15 days, according to the letter

FDA Lifts Curtain On The Secret Behind Magic Power Coffee

FDA's consumer advisory against a coffee product that contains an active drug ingredient for erectile dysfunction reflects the agency's growing capability to keep up with noncompliant firms that add drug substances to so-called dietary supplements

Scotland's MGB Plots Phase III For Promising Antibacterial

With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts